These days, most high-profile games are impossible to play without purchasing. But Slay the Spire 2's developers haven't just bucked that anti-piracy trend: they've punt it into the stratosphere. And ...

This raise will set the company up for years. With PYC's value sitting at $944.8 million at the close of trade on Friday, the raise will grow the size of the company by 69.2% in one fell swoop. The ...

PYC Therapeutics, a developer of RNA therapies for genetic diseases and capitalised at $933 million on the ASX, confirmed a $653 million equity raising on Monday morning after Street Talk revealed the ...

Game decompilations have been in the news on and off again for quite some time. It’s the act of reverse engineering games to run natively on PC (or any hardware, in theory). Now, there’s potential for ...

A look at the shareholders of PYC Therapeutics Limited (ASX:PYC) can tell us which group is most powerful. The group holding the most number of shares in the company, around 45% to be precise, is ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

If you’ve been following PYC Therapeutics (ASX:PYC), there is plenty to think about this week. The company is in the spotlight after its CEO, Rohan Hockings, stepped down with little warning. This ...

The S&P/ASX 200 Index is falling on Wednesday, with Flight Centre, Inghams, New Hope Corporation, and PYC Therapeutics shares declining significantly. Both Flight Centre and Inghams' share prices ...

PYC Therapeutics has built a pipeline of drug candidates addressing rare genetic diseases, with three assets now in clinical stages. The company’s strategy centers on using RNA therapeutics to ...

The dosing of patients with polycystic kidney disease is set to begin this month. Credit: SewCreamStudio / Shutterstock. PYC Therapeutics is set to begin Part B in its single ascending dose (SAD) ...